Alto Neuroscience (NYSE:ANRO) shares nosedived 66% Wednesday morning, the first trading session, after the company announced its psychiatric drug ALTO-100 had failed a key clinical study. After ...

Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary ...

Strong cash position expected to fund Alto’s planned operations through multiple near-term milestones across pipeline of independent programs – MOUNTAIN VIEW, Calif., October 22, 2024 ...